NextCell Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from NextCell Pharma
Access all reports
NextCell Pharma AB is a Swedish biopharmaceutical company specializing in the development of novel stromal cell therapies, primarily focusing on treatments for autoimmune and inflammatory diseases. Its flagship product, ProTrans, targets type 1 diabetes. The company also operates Cellaviva, the largest private stem cell bank in Scandinavia, which stores and processes stem cells from umbilical cords. NextCell Pharma integrates both therapeutic development and biobanking services within its operations. The company is headquartered in Huddinge, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
Ticker symbol
NXTCL
Country
🇸🇪 Sweden